Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out? Podcast By cover art

Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Listen for free

View show details

About this listen

 Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts. Further Listening: Trillion Dollar Shot Why WeightWatchers Wants in on Drugs Like Ozempic Sign up for WSJ’s free What’s News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
No reviews yet